Original Encounter with Antigen Determines Antigen-presenting Cell Imprinting of the Quality of the Immune Response in Mice

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2009 Dec 10

PMID 19997562

Citations 22

Authors

Valerie Abadie

Olivia Bonduelle

Darragh Duffy

Christophe Parizot

Bernard Verrier

Behazine Combadiere

Affiliations

Soon will be listed here.

Abstract

Background: Obtaining a certain multi-functionality of cellular immunity for the control of infectious diseases is a burning question in immunology and in vaccine design. Early events, including antigen shuttling to secondary lymphoid organs and recruitment of innate immune cells for adaptive immune response, determine host responsiveness to antigens. However, the sequence of these events and their impact on the quality of the immune response remain to be elucidated. Here, we chose to study Modified Vaccinia virus Ankara (MVA) which is now replacing live Smallpox vaccines and is proposed as an attenuated vector for vaccination strategies against infectious diseases.

Methodology/principal Findings: We analyzed in vivo mechanisms triggered following intradermal (i.d.) and intramuscular (i.m.) Modified Vaccinia virus Ankara (MVA) administration. We demonstrated significant differences in the antigen shuttling to lymphoid organs by macrophages (MPhis), myeloid dendritic cells (DCs), and neutrophils (PMNs). MVA i.d. administration resulted in better antigen distribution and more sustained antigen-presenting cells (APCs) recruitment into draining lymph nodes than with i.m. administration. These APCs, which comprise both DCs and MPhis, were differentially involved in T cell priming and shaped remarkably the quality of cytokine-producing virus-specific T cells according to the entry route of MVA.

Conclusions/significance: This study improves our understanding of the mechanisms of antigen delivery and their consequences on the quality of immune responses and provides new insights for vaccine development.

Citing Articles

Multilayer Adjuvanted Influenza Protein Nanoparticles Improve Intranasal Delivery and Antigen-Specific Immunity.

Park J, Pho T, Bhatnagar N, Mai L, Rodriguez-Otero M, Pal S ACS Nano. 2025; 19(7):7005-7025.

PMID: 39954231 PMC: 11867023. DOI: 10.1021/acsnano.4c14735.

Immune responses of cattle vaccinated by various routes with Mycobacterium bovis Bacillus Calmette-Guérin (BCG).

Palmer M, Hwang S, Kanipe C, Putz E, Fernandes L, Didkowska A BMC Vet Res. 2025; 21(1):19.

PMID: 39815253 PMC: 11734464. DOI: 10.1186/s12917-024-04452-7.

Intradermal but not intramuscular modified vaccinia Ankara immunizations protect against intravaginal tier2 simian-human immunodeficiency virus challenges in female macaques.

Bollimpelli V, Reddy P, Gangadhara S, Charles T, Burton S, Tharp G Nat Commun. 2023; 14(1):4789.

PMID: 37553348 PMC: 10409804. DOI: 10.1038/s41467-023-40430-7.

First Impressions Matter: Immune Imprinting and Antibody Cross-Reactivity in Influenza and SARS-CoV-2.

King S, Bryan S, Hilchey S, Wang J, Zand M Pathogens. 2023; 12(2).

PMID: 36839441 PMC: 9967769. DOI: 10.3390/pathogens12020169.

Cakala-Jakimowicz M, Kolodziej-Wojnar P, Puzianowska-Kuznicka M Cells. 2021; 10(11).

PMID: 34831371 PMC: 8621398. DOI: 10.3390/cells10113148.

References

Leon B, Lopez-Bravo M, Ardavin C . Monocyte-derived dendritic cells formed at the infection site control the induction of protective T helper 1 responses against Leishmania. Immunity. 2007; 26(4):519-31. DOI: 10.1016/j.immuni.2007.01.017. View

Shen X, Wong S, Buck C, Zhang J, Siliciano R . Direct priming and cross-priming contribute differentially to the induction of CD8+ CTL following exposure to vaccinia virus via different routes. J Immunol. 2002; 169(8):4222-9. DOI: 10.4049/jimmunol.169.8.4222. View

Bonneau M, Epardaud M, Payot F, Niborski V, Thoulouze M, Bernex F . Migratory monocytes and granulocytes are major lymphatic carriers of Salmonella from tissue to draining lymph node. J Leukoc Biol. 2005; 79(2):268-76. DOI: 10.1189/jlb.0605288. View

Seder R, Darrah P, Roederer M . T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol. 2008; 8(4):247-58. DOI: 10.1038/nri2274. View

Iga M, Boissonnas A, Mahe B, Bonduelle O, Combadiere C, Combadiere B . Single CX3CL1-Ig DNA administration enhances T cell priming in vivo. Vaccine. 2007; 25(23):4554-63. DOI: 10.1016/j.vaccine.2007.04.028. View

Meseda C, Garcia A, Kumar A, Mayer A, Manischewitz J, King L . Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model. Virology. 2005; 339(2):164-75. DOI: 10.1016/j.virol.2005.06.002. View

Amara R, Nigam P, Sharma S, Liu J, Bostik V . Long-lived poxvirus immunity, robust CD4 help, and better persistence of CD4 than CD8 T cells. J Virol. 2004; 78(8):3811-6. PMC: 374286. DOI: 10.1128/jvi.78.8.3811-3816.2004. View

Estcourt M, Letourneau S, McMichael A, Hanke T . Vaccine route, dose and type of delivery vector determine patterns of primary CD8+ T cell responses. Eur J Immunol. 2005; 35(9):2532-40. DOI: 10.1002/eji.200535184. View

Drexler I, Staib C, Kastenmuller W, Stevanovic S, Schmidt B, Lemonnier F . Identification of vaccinia virus epitope-specific HLA-A*0201-restricted T cells and comparative analysis of smallpox vaccines. Proc Natl Acad Sci U S A. 2003; 100(1):217-22. PMC: 140931. DOI: 10.1073/pnas.262668999. View

10.

Precopio M, Betts M, Parrino J, Price D, Gostick E, Ambrozak D . Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses. J Exp Med. 2007; 204(6):1405-16. PMC: 2118607. DOI: 10.1084/jem.20062363. View

11.

Cosma A, Buhler S, Nagaraj R, Staib C, Hammarin A, Wahren B . Neutralization assay using a modified vaccinia virus Ankara vector expressing the green fluorescent protein is a high-throughput method to monitor the humoral immune response against vaccinia virus. Clin Diagn Lab Immunol. 2004; 11(2):406-10. PMC: 371213. DOI: 10.1128/cdli.11.2.406-410.2004. View

12.

Miller J, van der Most R, Akondy R, Glidewell J, Albott S, Masopust D . Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. Immunity. 2008; 28(5):710-22. DOI: 10.1016/j.immuni.2008.02.020. View

13.

Carroll M, Moss B . Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line. Virology. 1997; 238(2):198-211. DOI: 10.1006/viro.1997.8845. View

14.

Stittelaar K, Kuiken T, de Swart R, van Amerongen G, Vos H, Niesters H . Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques. Vaccine. 2001; 19(27):3700-9. DOI: 10.1016/s0264-410x(01)00075-5. View

15.

Hammarlund E, Lewis M, Hansen S, Strelow L, Nelson J, Sexton G . Duration of antiviral immunity after smallpox vaccination. Nat Med. 2003; 9(9):1131-7. DOI: 10.1038/nm917. View

16.

Earl P, Americo J, Wyatt L, Eller L, Whitbeck J, Cohen G . Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature. 2004; 428(6979):182-5. DOI: 10.1038/nature02331. View

17.

Eichelberger M . Virus-specific antigen presentation by different subsets of cells from lung and mediastinal lymph node tissues of influenza virus-infected mice. J Virol. 1995; 69(10):6359-66. PMC: 189535. DOI: 10.1128/JVI.69.10.6359-6366.1995. View

18.

Drexler I, Heller K, Wahren B, Erfle V, Sutter G . Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells. J Gen Virol. 1998; 79 ( Pt 2):347-52. DOI: 10.1099/0022-1317-79-2-347. View

19.

Villadangos J, Schnorrer P . Intrinsic and cooperative antigen-presenting functions of dendritic-cell subsets in vivo. Nat Rev Immunol. 2007; 7(7):543-55. DOI: 10.1038/nri2103. View

20.

Phelps A, Gates A, Hillier M, Eastaugh L, Ulaeto D . Comparative efficacy of modified vaccinia Ankara (MVA) as a potential replacement smallpox vaccine. Vaccine. 2006; 25(1):34-42. DOI: 10.1016/j.vaccine.2006.07.022. View